ABVC Biopharma Announced That The First Subject Was Enrolled At The University Of California San Francisco Medical Center, Joining The Five Taiwan Sites That Have Begun Patient Enrollment For The Company's ADHD Phase 2 Part 2 Study
Portfolio Pulse from Benzinga Newsdesk
ABVC Biopharma has enrolled its first subject at the University of California San Francisco Medical Center for the ADHD Phase 2 Part 2 study, joining five Taiwan sites that have already begun patient enrollment.
June 12, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ABVC Biopharma's ADHD Phase 2 Part 2 study expands to the University of California San Francisco Medical Center, potentially accelerating patient enrollment and study progress.
The expansion of ABVC Biopharma's ADHD Phase 2 Part 2 study to the University of California San Francisco Medical Center is likely to have a positive short-term impact on the company's stock price. This is because the enrollment of the first subject at the new site, in addition to the five Taiwan sites, could potentially accelerate patient enrollment and study progress, bringing the company closer to potential regulatory approval and commercialization of its ADHD treatment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100